Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure
ConditionAcute Liver Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorKing Edward Medical University
About this trial
This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).
Eligibility criteria
Qualifiers
Male or female, aged 18-60 years
Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition/EASL criteria)
Etiology other than acetaminophen overdose (viral hepatitis HAV/HBV/HEV, non-acetaminophen drug-induced liver injury, or idiopathic)
No NAC treatment received for current episode prior to enrollment
Disqualifiers
History of chronic liver disease or cirrhosis
Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes
Prior liver transplant or current transplant candidacy
Known allergy/contraindication to NAC
Trial design
Treatments tested in this trial
- N Acetyl Cysteine
- Standard supportive care
Treatment groups
62 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov